Novel Type 1 5a-Reductase Inhibitors With Antiproliferative Potential On LNCaP Cells

    June 2023 in “ Oriental Journal of Chemistry/Oriental journal of chemistry ”
    Marisa Cabeza, Luis A. Menes, Evelyn Fuentes … Yvonne Heuze
    Studysummary This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on orientjchem.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Activity of Steroid 4 and Derivatives 4a–4f as Inhibitors of the Enzyme 5α-Reductase Type 1 Bioorganic & medicinal chemistry · 2018
    2. New Ester Derivatives of Dehydroepiandrosterone as 5α-Reductase Inhibitors Steroids · 2011
    3. Finasteride: A Slow-Binding 5-Alpha-Reductase Inhibitor Biochemistry · 1993

    Related research 3

    1. Evaluation of the Therapeutic Effects of AGA Drugs by Measuring Finasteride, Dutasteride, and Dihydrotestosterone in Hair Clinica Chimica Acta · 2023
    2. The Effects of Finasteride on Scalp Skin and Serum Androgen Levels in Men with Androgenetic Alopecia Journal of The American Academy of Dermatology · 1999
    3. The Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Scalp Skin Testosterone and Dihydrotestosterone Concentrations in Patients with Male Pattern Baldness The Journal of Clinical Endocrinology and Metabolism · 1994